Home › Epigenomics Reports 81 Percent Drop in Q2 Revenues; Takeover Bid Fails

Epigenomics Reports 81 Percent Drop in Q2 Revenues; Takeover Bid Fails

Aug 09, 2017

NEW YORK (GenomeWeb) – Epigenomics reported today that its second quarter revenues dropped 81 percent due to lower orders of its Epi proColon colorectal cancer test and a continued lack of reimbursement coverage for its products.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Nov
05
Featured Webinar

Overcoming Challenges in Solid Tumor Testing with Advanced AI

Sponsored by
Sophia Genetics

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.

What's Popular?

In Molecular Diagnostics

  1. Thermo Fisher Scientific Gets CE-IVD Mark for NGS Cancer Test

  2. Singlera Genomics Presents Data on Cell-Free DNA Methylation Test for Early Cancer Detection

    Premium

  3. FDA Approves Myriad Genetics BRCA CDx With Pfizer's Metastatic Breast Cancer Drug

  4. Roche Diagnostics' Revenues Grow 6 Percent in First Nine Months of 2018

  5. Abbott Q3 Dx Business Grows 43 Percent

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2018 GenomeWeb LLC.  All Rights Reserved.